Drugs / Chimeric Antigen Receptor T Cells (CAR-T)
Chimeric Antigen Receptor T Cells (CAR-T)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07458659 | Jun 2026 → Jun 2028 expected | plasma cell myeloma | Chulalongkorn University | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06996132 | May 2025 → May 2027 expected | aggressive B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric Antigen Receptor T Cells (CAR-T) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07458659 ↗ |
| Modality | Cell therapy | “CAR-T cell infusion” NCT06996132 ↗ |
| Route | Intravenous | “subsequently reinfused intravenously through a peripheral vein” NCT07458659 ↗ |